Focus: Bel Air Pharmaceuticals is a newly founded (2024) specialty pharmaceutical company headquartered in Beverly Hills, CA, focused on commercializing branded drugs in wound care, diagnostics, and pain management.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bel Air Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bel Air Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver at 60% of company revenue; patent protection extends to 2033 providing near-decade of exclusivity.
Help build intelligence for Bel Air Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Second-largest revenue contributor but no LOE date available; approaching loss of exclusivity creates near-term revenue headwind.
Post-LOE generic formulation with minimal Part D spending; represents commoditized market position.
Post-LOE generic formulation with minimal Part D spending; represents commoditized market position.
Established antihypertensive with alpha/beta-blocking properties; approaching exclusivity loss without disclosed Part D revenue suggests niche positioning.
Post-LOE generic formulation; minimal revenue contribution.
Oral formulation of itraconazole with LOE approaching 2028; represents near-term patent cliff risk.
Post-LOE generic formulation; minimal revenue contribution.
Post-LOE generic formulation; minimal revenue contribution.
Post-LOE generic formulation; minimal revenue contribution.
4 discontinued, 8 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo